There's been great hope among doctors for Cobenfy, which was approved in September, because it acts in the brain differently than other schizophrenia drugs. Instead of blocking dopamine receptors ...

Cobenfy will cost $1,850 for a month's supply or $22,500 annually before insurance and other rebates, according to Bristol ...

BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook ...

Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...

Last September, the F.D.A. approved Cobenfy, the first novel antipsychotic treatment in decades. Heart Failure Hope: Growing awareness and new drugs could help change the trajectory for patients ...

Cobenfy comes as a capsule. It received Food and Drug Administration approval on Sept. 26 as a treatment for schizophrenia, then launched onto the U.S. market in late October. By Bristol Myers ...

Cobenfy is a combination of a muscarinic M1 ... It came just a few days after AbbVie agreed a $10.1 billion deal to buy antibody-drug conjugate developer ImmunoGen. CNS is a key therapeutic ...

For around 70 years, the treatment of schizophrenia has relied almost entirely on drugs that block dopamine receptors, so Cobenfy's action on cholinergic receptors offers a brand new way to treat ...

Bristol-Myers Squibb's Cobenfy launch shows strong initial sales ... term growth and shareholder return focus. LOE risks for key drugs like Yervoy and Eliquis and cautious 2025 guidance suggest ...

Hope surged in September 2024 when the US Food and Drug Administration (FDA) approved Cobenfy (xanomeline-trospium chloride), the first-in-class antipsychotic with a novel mechanism that targets ...